1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp.

BCTXW
BriaCell Therapeutics Corp.US flagNASDAQ Capital Market
0.00
USD
-NaN
- -
1,695.00Market Cap
BriaCell Therapeutics Corp.
BCTXW
(NASDAQ Capital Market)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-1
-1
- -
-8
-3
-2
-3
-4
-5
-4
-14
-27
-20
-5
-19
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
1
4
2
1
- -
1
1
1
1
-1
-4
57
41
25
-4
10
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
1
12
10
9
- -
1
1
1
1
-1
-4
28
10
-4
-3
12
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-3.98
- -
- -
- -
- -
- -
- -
- -
- -
-173.87
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
1
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Oct'25
Jan'25
Apr'25
Total Current Assets
8
7
15
Cash, Cash Equivalents & STI
6
5
12
Accounts Receivable, Net
2
2
2
Inventories
- -
- -
- -
Total Current Liabilities
5
5
4
Payables & Accruals
5
5
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-10,376.01%
-135%
-28.92%
Free Cash Flow
86.23%
119.51%
3.53%
Net Income, GAAP
24.5%
44.44%
-76.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Longbio-b (1779.HK)
Arcellx, Inc. (ACLX)
Mesoblast Limited (MSB.AX)
Mereo BioPharma Group plc (MREO)
Galmed Pharmaceuticals Ltd. (GLMD)
Vanta Bioscience Limited (VANTABIO.BO)
Business
BriaCell Therapeutics Corp. is a leading clinical-stage biotechnology firm dedicated to revolutionizing cancer treatment through advanced cellular immunotherapies. The company is actively enrolling patients in a pivotal Phase 3 clinical investigation for its primary therapeutic candidate, Bria-IMT™, targeting metastatic breast cancer when combined with an immune checkpoint inhibitor. This study has received Fast Track designation from the FDA, and its Data Safety Monitoring Board has consistently provided positive safety recommendations. Furthermore, BriaCell is developing innovative personalized, off-the-shelf treatments, including Bria-OTS™ and Bria-OTS+™, intended for breast cancer and broadening its scope to encompass prostate cancer, lung cancer, and melanoma. The company maintains an active clinical trial collaboration with Incyte Corporation, focused on assessing various combinations involving Bria-IMT™ with Incyte's compounds. Most recently, in a strategic expansion, BriaCell's subsidiary, BriaPro Therapeutics, announced an AI-driven research partnership with Receptor.AI to develop small-molecule cancer therapeutics. BriaCell Therapeutics Corp. operates out of West Vancouver, Canada, and Philadelphia, Pennsylvania.